September 1, 2008 - Depression and heart disease are the two leading disorders with the strongest contributions to the global burden of disease, and several large studies suggest the two are intertwined.

September 3, 2008 - Edwards Lifesciences Corp. today said it received FDA approval for the Carpentier-Edwards PERIMOUNT Magna mitral heart valve, which the company plans to immediately launch for sale in the U.S.

Designed for the treatment of mitral valve disease, one of the most common forms of heart valve disease in the world, the PERIMOUNT Magna mitral valve is a pericardial tissue-based bioprosthetic device that replaces a patient’s diseased mitral valve. Industry estimates indicate that there will be 35,000-40,000 surgical mitral valve replacements in the U.S. in 2008.

Edwards Lifesciences Corp. produces the Carpentier-Edwards

The PERIMOUNT Magna mitral valve was launched in Europe in September 2005. It incorporates features of the Carpentier-Edwards PERIMOUNT mitral valve, which has demonstrated 16 years of durability, including the treatment of the bovine pericardial tissue leaflets with the Carpentier-Edwards ThermaFix process.

September 2008

September 2, 2008 – Two recent studies demonstrate the economical value of cardiac imaging, showing MDCT to be cost-effective for men and cost-saving for women, and demonstrating how echo is cost-effective in determining patient eligibility for ICDs (implantable cardioverter-defibrillators).

September 2, 2008 - Initial safety and efficacy data, presented at the European Society of Cardiology Congress in Munich, Germany on the Medtronic Inc. investigational EnRhythm MRI SureScan Pacing System shows promise for a potential solution for patients receiving their first pacemaker and needing an MRI scan.

September 2, 2008 - Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings announced from the CARDia trial, said the Society for Cardiovascular Angiography and Interventions (SCAI)

The one-year findings of the new study indicate these patients can safely choose to undergo angioplasty and stenting rather than open-heart surgery.

September 2, 2008 - Data from the landmark SYNTAX trial indicates patients with very complex coronary artery disease can safely choose to be treated with angioplasty and drug-eluting stents rather than open-heart surgery, said the Society for Cardiovascular Angiography and Interventions (SCAI).

The one-year results of SYNTAX also show that most patients with left main and multi-vessel disease who undergo angioplasty and stenting will not need a second revascularization procedure in the first year.

September 2, 2008 – Boston Scientific Corp. today announced positive one-year results from the European and Intercontinental launch phases of its global TAXUS OLYMPIA registry, the world’s largest post-approval, prospective registry for a single drug-eluting stent (DES).

September 2, 2008 - Boston Scientific Corp. this past week said the U.S. District Court of Marshall, TX found two patents of Medtronic Inc. unenforceable for inequitable conduct during the prosecution of the patents before the U.S. Patent and Trademark Office.

September 2, 2008 - Terumo Cardiovascular Systems said today it filed a patent infringement complaint Aug. 21 in the Northern District of California against Maquet Cardiovascular LLC, alleging Maquet’s Vasoview Endoscopic Vessel Harvesting System infringes a Terumo patent.

Terumo said the complaint requests an injunction against further sales of the Maquet product in the U.S.

Terumo sells the VirtuoSaph Endoscopic Vessel Harvesting System in the U.S., Japan, Asia and Europe.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now